Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Other Stockholders Equity: ¥458 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603676 Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
79 GF Score
Price ¥9.35
GF Value ¥8.91
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xizang Weixinkang Pharmaceutical Co Other Stockholders Equity?

Xizang Weixinkang Pharmaceutical Co SHSE:603676 +0.75% 79 Other Stockholders Equity is ¥458 Mil as of Mar. 2026. GuruFocus rates SHSE:603676 with a GF Score™ of 79/100 and a GF Value™ of ¥8.91 (Fairly Valued). The stock has 2 warning signs investors should review.

Xizang Weixinkang Pharmaceutical Co's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ¥458 Mil.

Xizang Weixinkang Pharmaceutical Co's quarterly Other Stockholders Equity declined from Sep. 2025 (¥443 Mil) to Dec. 2025 (¥124 Mil) but then increased from Dec. 2025 (¥124 Mil) to Mar. 2026 (¥458 Mil).

Xizang Weixinkang Pharmaceutical Co's annual Other Stockholders Equity declined from Dec. 2023 (¥143 Mil) to Dec. 2024 (¥110 Mil) but then increased from Dec. 2024 (¥110 Mil) to Dec. 2025 (¥124 Mil).

Xizang Weixinkang Pharmaceutical Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xizang Weixinkang Pharmaceutical Co Other Stockholders Equity Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.80 133.55 143.13 109.55 124.19

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 443.25 109.25 442.99 124.19 457.59
SHSE:603676
79GF Score
Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xizang Weixinkang Pharmaceutical Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ¥458 Mil mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Other Stockholders Equity of ¥458 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors.
Is Xizang Weixinkang Pharmaceutical Co's Other Stockholders Equity too high?
Xizang Weixinkang Pharmaceutical Co's current Other Stockholders Equity is ¥458 Mil. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Other Stockholders Equity compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Other Stockholders Equity of ¥458 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Other Stockholders Equity is ¥458 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.91, compared to a current price of ¥9.35 — trading 4.9% above its estimated fair value. The current Other Stockholders Equity is ¥458 Mil. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Other Stockholders Equity is ¥458 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?

Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥9.35 is trading 4.9% above its estimated GF Value™ of ¥8.91. GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603676:

  • Other Stockholders Equity: ¥458 Mil
  • GF Value™: ¥8.91 vs. price of ¥9.35 (4.9% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xizang Weixinkang Pharmaceutical Co Business Description

Address Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
79GF Score

Get the complete analysis for SHSE:603676

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.35
Price
¥8.91
GF Value